Developed in collaboration with Dr Rob Kelly, Dr Vanessa Stedman, and Victoria Biddick.
GLP-1 agonist weight loss medications are now available in NZ. What are they and how do they work?
Based on the active ingredient semaglutide and commonly marketed under the names Wegovy or Ozempic, GLP-1 agonists mimic GLP-1 which is a hormone released in the GI tract after eating. Given in the form of a weekly injection, these drugs bind to and activate the GLP-1 receptors, basically telling the body to behave as if you’ve just eaten. They slow down the rate at which food empties from the stomach, decrease blood sugar and signal to the brain that you are full leading to appetite suppression.
General practitioners can prescribe Wegovy for weight loss, expanding access to a medication originally developed for type 2 diabetes.

What are the downsides to GLP-1 agonist drugs?
The most common issues are gastrointestinal symptoms such as diarrhoea, constipation, bloating, abdominal pain, vomiting and nausea. Less prevalent but more serious side effects include pancreatitis, bowel blockages and biliary disease (1-3).
They can lead to significant loss of lean muscle mass especially when associated with patients at risk for sarcopenia (4).
They also make nutrient absorption harder, increasing the risk of poor nutrition.
What about long-term use?
Unlike surgical interventions, there are no lasting effects. This means that when the drug is withdrawn patients can regain weight if they have not adopted permanent lifestyle changes (5,6). For this reason, some weight loss practitioners work alongside dieticians and psychologists to increase the likelihood of long-term weight stability post treatment.

What are the experts saying?
Dr Vanessa Stedman, General Practitioner.
Medicines like Wegovy and Ozempic, originally developed for type 2 diabetes, are now also used to help with weight loss in people with a higher BMI or weight-related health problems. They work by reducing appetite and improving blood sugar control but should only be prescribed after a proper medical assessment and discussion of the benefits, possible side effects, and costs.
Common side effects include feeling sick, vomiting, diarrhoea, or constipation, and in rare cases more serious problems such as inflammation of the pancreas or gallbladder.
These medicines work best when combined with healthy eating and regular activity and stopping them often leads to weight regain if other changes aren’t in place. Even if your appetite is smaller, it’s important to eat enough protein to protect your muscles, and to include plenty of vegetables, fruit, whole grains, and healthy fats, as well as staying well hydrated.
Victoria Biddick, Nutritionist.
The reclassification of Wegovy from a type 2 diabetes treatment to a prescription weight-loss medication represents a significant development in New Zealand’s healthcare and nutrition landscape.
There’s no doubt that Wegovy is a powerful tool for appetite suppression and weight loss (6). However, its effectiveness is maximised when paired with nutrition and lifestyle support to help manage potential side effects (7).
This sentiment is echoed by Lily Henderson, spokesperson for Dietitians NZ , in a recent press release GLP-1 Press Release:
"These medications change how people eat – but they don’t change what the body needs."
Research consistently shows that individuals who lose weight gradually through sustainable lifestyle changes are more likely to maintain their weight loss (8). This is where the expertise of a registered dietitian or nutritionist becomes essential to optimise nutrient intake , prevent deficiencies , preserve muscle mass , support gut health , and manage side effects.
As a non-diet practitioner , I also focus on the why and how of eating not just the what. We don’t eat solely in response to hunger . While weight is often framed as a matter of personal responsibility, this perspective overlooks the external forces that shape our food choices . Our current food environment is designed in ways that promote weight gain (9). It encourages the consumption of inexpensive, energy-dense, highly processed foods that are widely available , aggressively marketed , and often more accessible than healthier options . These systemic factors make it difficult for many people to make nourishing choices , regardless of their intentions or willpower (8).
When GLP-1 medications are discontinued , appetite typically returns . If we haven’t addressed the underlying eating behaviours that contributed to weight gain—such as emotional eating , habitual patterns , or environmental triggers —it’s likely that we’ll revert to those same behaviours, leading to weight regain (5,6).
“I’m not judging anyone taking GLP-1 drugs but encouraging them to get a good support network around them, so they make sustainable changes that last beyond the medication.”
Dr Rob Kelly, PhD in Protein Chemistry.
Proteins are a fundamental part of nutrition but not all proteins are the same. Impact on lean muscle mass and digestibility are relevant to consider in the context of GLP-1 agonist medications.
Proteins are made up of amino acids, and the body uses different amino acids in different ways, with some proteins richer in those that help maintain lean muscle mass. Some proteins are also more rapidly digestible than others, which may be helpful if digestion slows as a result of GLP-1 treatment.
Summary
GLP-1 agonist weight loss medications such as Wegovy are important new tools for weight management.
- As a prescription medication, consultation with your general practitioner is an essential part of considering and planning their use.
- Lifestyle is an important consideration, including exercise and nutrition.
- Protein and protein quality are essential considerations in a nutritional plan.
References
Wharton et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, Vol 134, 2022. https://doi.org/10.1080/00325481.2021.2002616
Long et al. GLP-1 agonists: A review for emergency clinician. The American Journal of Emergency Medicine, Vol 78, 89-94, 2024. https://doi.org/10.1016/j.ajem.2024.01.010
Filippatos et al. Adverse effects of GLP-1 Receptor Agonists. The Review of Diabetic Studies, Vol 11, No. 3-4, 2014/2015. DOI 10.1900/RDS.2014.11.202
Memel et al. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr. Nutr Rep. Apr 28;14(1):63, 2025. DOI: 10.1007/s13668-025-00649-w
Wilding et al. Weight gain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;245:1553-1564.
https://doi.org/10.1111/dom.14725
Rubino et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 2021 Mar 23;325(14):1-12. doi: 10.1001/jama.2021.3224
Dietitians NZ. (2025, July 1). GLP-1 Press Release. https://dietitians.org.nz/Web/Web/Resources-Media/Latest-News-Articles/GLP-1Press-Release.aspx
Bacon, L., & Aphramor, L. (2011). Weight science: evaluating the evidence for a paradigm shift. Nutrition Journal, 10(1), 1-13. https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-10-9
Mackay, Sally; Garton, Kelly; Gerritsen, Sarah; Sing, Fiona; Swinburn, Boyd (2021). How healthy are Aotearoa New Zealand's food environments? Assessing the impact of recent food policies 2018-2021. The University of Auckland. Report. https://doi.org/10.17608/k6.auckland.16968478